View Item 

Show simple item record

Erectile function after stereotactic body radiotherapy for localized prostate cancer
dc.contributor.authorDess, Robert T.
dc.contributor.authorHartman, Holly E.
dc.contributor.authorAghdam, Nima
dc.contributor.authorJackson, William C.
dc.contributor.authorSoni, Payal D.
dc.contributor.authorAbugharib, Ahmed E.
dc.contributor.authorSuy, Simeng
dc.contributor.authorDesai, Neil B.
dc.contributor.authorZumsteg, Zachary S.
dc.contributor.authorMehra, Rohit
dc.contributor.authorMorgan, Todd M.
dc.contributor.authorFeng, Felix Y.
dc.contributor.authorHamstra, Daniel A.
dc.contributor.authorSchipper, Matthew J.
dc.contributor.authorCollins, Sean P.
dc.contributor.authorSpratt, Daniel E.
dc.date.accessioned2018-02-05T16:26:58Z
dc.date.available2019-03-01T21:00:19Zen
dc.date.issued2018-01
dc.identifier.citationDess, Robert T.; Hartman, Holly E.; Aghdam, Nima; Jackson, William C.; Soni, Payal D.; Abugharib, Ahmed E.; Suy, Simeng; Desai, Neil B.; Zumsteg, Zachary S.; Mehra, Rohit; Morgan, Todd M.; Feng, Felix Y.; Hamstra, Daniel A.; Schipper, Matthew J.; Collins, Sean P.; Spratt, Daniel E. (2018). "Erectile function after stereotactic body radiotherapy for localized prostate cancer." BJU International 121(1): 61-68.
dc.identifier.issn1464-4096
dc.identifier.issn1464-410X
dc.identifier.urihttps://hdl.handle.net/2027.42/141067
dc.publisherWiley Periodicals, Inc.
dc.subject.othersexual function
dc.subject.otherstereotactic body radiation therapy
dc.subject.other#ProstateCancer
dc.subject.other#PCSM
dc.subject.othererectile function
dc.subject.otherpatient‐reported outcomes
dc.subject.otherSBRT
dc.titleErectile function after stereotactic body radiotherapy for localized prostate cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141067/1/bju13962_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141067/2/bju13962.pdf
dc.identifier.doi10.1111/bju.13962
dc.identifier.sourceBJU International
dc.identifier.citedreferenceChen RC, Chang P, Vetter RJ et al. Recommended patient‐reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst 2014; 106: pii: dju132.
dc.identifier.citedreferenceHamdy FC, Donovan JL, Lane JA et al. 10‐year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415 – 24. PubMed PMID: 27626136
dc.identifier.citedreferenceJohnston TJ, Shaw GL, Lamb AD et al. Mortality among men with advanced prostate cancer excluded from the ProtecT trial. Eur Urol 2017; 71: 381 – 8
dc.identifier.citedreferenceSanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate‐cancer survivors. N Engl J Med 2008; 2008: 1250 – 61
dc.identifier.citedreferenceHoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 2003; 97: 1653 – 62
dc.identifier.citedreferenceDonovan JL, Hamdy FC, Lane JA et al. Patient‐reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375: 1425 – 37. PubMed PMID: 27626365
dc.identifier.citedreferenceFicarra V, Novara G, Artibani W et al. Retropubic, laparoscopic, and robot‐assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009; 55: 1037 – 63
dc.identifier.citedreferenceLaviana AA, Ilg AM, Veruttipong D et al. Utilizing time‐driven activity‐based costing to understand the short‐and long‐term costs of treating localized, low‐risk prostate cancer. Cancer 2016; 122: 447 – 55
dc.identifier.citedreferenceHalpern JA, Sedrakyan A, Hsu WC et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer 2016; 122: 2496 – 504
dc.identifier.citedreferenceDess RT, Jackson WC, Suy S et al. Predictors of multidomain decline in health‐related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer 2017; 123: 1635 – 42
dc.identifier.citedreferenceKing CR, Collins S, Fuller D et al. Health‐related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi‐institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 2013; 87: 939 – 45
dc.identifier.citedreferenceLukka H, Stephanie P, Bruner D et al. Patient‐reported outcomes in NRG Oncology/RTOG 0938, a randomized phase 2 study evaluating 2 ultrahypofractionated regimens (UHRs) for prostate cancer. Int J Radiat Oncol Biol Phys 2016; 94: 2
dc.identifier.citedreferenceThe PACE Study: International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventionally fractionated radiotherapy vs SBRT for early stage organ‐confined prostate cancer. Available at: http://www.isrctn.com/ISRCTN17627211. Accessed 10 November 2016
dc.identifier.citedreferenceWidmark AGA, Beckman L, Thellenber‐Karlsson C et al. Extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate‐risk prostate cancer: Early toxicity results from the Scandinavian randomized phase III trial “HYPO‐RT‐PC.”. 2016 ASTRO Annual Meeting Abstract LBA‐5. 2016.
dc.identifier.citedreferenceKimura M, Yan H, Rabbani Z et al. Radiation‐induced erectile dysfunction using prostate‐confined modern radiotherapy in a rat model. J Sex Med 2011; 8: 2215 – 26
dc.identifier.citedreferenceAlemozaffar M, Regan MM, Cooperberg MR et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306: 1205 – 14
dc.identifier.citedreferenceSzymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health‐related quality of life among prostate cancer survivors. Urology 2010; 76: 1245 – 50
dc.identifier.citedreferenceRosen R, Cappelleri J, Smith M, Lipsky J, Pena B. Development and evaluation of an abridged, 5‐item version of the International Index of Erectile Function (IIEF‐5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319 – 26
dc.identifier.citedreferenceChen LN, Suy S, Uhm S et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 2013; 8: 1
dc.identifier.citedreferenceNIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83 – 90. eng.
dc.identifier.citedreferenceWiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2010; 78: 442 – 8
dc.identifier.citedreferenceFransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy‐induced side effects. Support Care Cancer 2001; 9: 187 – 98
dc.identifier.citedreferenceChen RC, Clark JA, Talcott JA. Individualizing quality‐of‐life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009; 27: 3916 – 22
dc.identifier.citedreferenceSelvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120: 151 – 7 eng.
dc.identifier.citedreferenceAraujo AB, Mohr BA, McKinlay JB. Changes in sexual function in middle‐aged and older men: Longitudinal data from the Massachusetts Male Aging Study. J Am Geriatr Soc 2004; 52: 1502 – 9
dc.identifier.citedreferenceChen RC, Basak R, Meyer A‐M et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient‐reported quality of life among men with localized prostate cancer. JAMA 2017; 317: 1141 – 50
dc.identifier.citedreferenceBarocas DA, Alvarez J, Resnick MJ et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient‐reported outcomes after 3 years. JAMA 2017; 317: 1126 – 40
dc.identifier.citedreferenceLee JY, Spratt DE, Liss AL, McLaughlin PW. Vessel‐sparing radiation and functional anatomy‐based preservation for erectile function after prostate radiotherapy. Lancet Oncol 2016; 17: e198 – 208
dc.identifier.citedreferenceSpratt DE, Lee JY, Dess RT et al. Vessel‐sparing radiotherapy for localized prostate cancer to preserve erectile function: a single‐arm phase 2 trial. Eur Urol 2017; https://doi.org/10.1016/j.eururo.2017.02.007. [Epub ahead of print]
dc.identifier.citedreferenceD’Amico AV, Chen M‐H, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289 – 95
dc.identifier.citedreferenceJones CU, Hunt D, McGowan DG et al. Radiotherapy and short‐term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107 – 18
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bju13962_am.pdf
Size:
347.4KB
Format:
PDF
View/Open
Name:
bju13962.pdf
Size:
211.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.